Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naselsky

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
Journal of Thoracic Disease|August 14, 2025
Using Vizient database for benchmarking pulmonary resection outcomesAnuj Shah, Duc T Nguyen, Swetha Mulpur, et al.
Molecular Carcinogenesis|March 23, 2022
Transglutaminase 2 enhances hepatocyte growth factor signaling to drive the mesothelioma cancer cell phenotypeWarren Naselsky, Gautam Adhikary, Suruchi Shrestha, et al.
Bioorganic & Medicinal Chemistry|December 1, 1995
Synthesis of a selective alpha-2A adrenoceptor antagonist, BRL 48962, and its characterization at cloned human alpha-adrenoceptorsL J Beeley, J M Berge, H Chapman, et al.
Surgical Endoscopy|June 30, 2026
Comparative long-term outcomes of Heller myotomy and peroral endoscopic myotomySamar Semaan, Cynthia Kassab, Warren C Naselsky, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1997
Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-1L adrenoceptor in tissue selectivity, part IA Leonardi, J P Hieble, L Guarneri, et al.
Molecular Carcinogenesis|December 23, 2022
Mesothelioma cancer cells are glutamine addicted and glutamine restriction reduces YAP1 signaling to attenuate tumor formationGautam Adhikary, Suruchi Shrestha, Warren Naselsky, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|November 19, 2004
Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediatorsDouglas G Johns, Zhaohui Ao, Diane Naselsky, et al.
Peptides|September 8, 2004
Differential levels of "urotensin-II-like" activity determined by radio-receptor and radioimmuno-assaysNambi Aiyar, Brian Guida, Zhaohui Ao, et al.
Indian Journal of Thoracic and Cardiovascular Surgery|July 15, 2026
Management of Harlequin syndrome in veno-arterial extracorporeal membrane oxygenationJustin Robinson, Jason Ejimogu, Warren Naselsky, et al.
Perfusion|November 23, 2024
Non-intensive care unit feasibility for ambulatory veno-venous extracorporeal membrane oxygenation patientsAakash Shah, Stephen Stachnik, Joshua L Leibowitz, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Journal of Thoracic Disease|August 14, 2025
Using Vizient database for benchmarking pulmonary resection outcomesAnuj Shah, Duc T Nguyen, Swetha Mulpur, et al.
Molecular Carcinogenesis|March 23, 2022
Transglutaminase 2 enhances hepatocyte growth factor signaling to drive the mesothelioma cancer cell phenotypeWarren Naselsky, Gautam Adhikary, Suruchi Shrestha, et al.
Bioorganic & Medicinal Chemistry|December 1, 1995
Synthesis of a selective alpha-2A adrenoceptor antagonist, BRL 48962, and its characterization at cloned human alpha-adrenoceptorsL J Beeley, J M Berge, H Chapman, et al.
Surgical Endoscopy|June 30, 2026
Comparative long-term outcomes of Heller myotomy and peroral endoscopic myotomySamar Semaan, Cynthia Kassab, Warren C Naselsky, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1997
Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-1L adrenoceptor in tissue selectivity, part IA Leonardi, J P Hieble, L Guarneri, et al.
Molecular Carcinogenesis|December 23, 2022
Mesothelioma cancer cells are glutamine addicted and glutamine restriction reduces YAP1 signaling to attenuate tumor formationGautam Adhikary, Suruchi Shrestha, Warren Naselsky, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|November 19, 2004
Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediatorsDouglas G Johns, Zhaohui Ao, Diane Naselsky, et al.
Peptides|September 8, 2004
Differential levels of "urotensin-II-like" activity determined by radio-receptor and radioimmuno-assaysNambi Aiyar, Brian Guida, Zhaohui Ao, et al.
Indian Journal of Thoracic and Cardiovascular Surgery|July 15, 2026
Management of Harlequin syndrome in veno-arterial extracorporeal membrane oxygenationJustin Robinson, Jason Ejimogu, Warren Naselsky, et al.
Perfusion|November 23, 2024
Non-intensive care unit feasibility for ambulatory veno-venous extracorporeal membrane oxygenation patientsAakash Shah, Stephen Stachnik, Joshua L Leibowitz, et al.
Pageof 4